Delaying and shortening the duration of treatment with CDK4/6 inhibitors in patients with metastatic breast cancer leads to similar survival outcomes while reducing toxicity and achieving substantial cost savings, the SONIA trial shows. Read more ➡️ https://bit.ly/3Oqw7aX
Comments